What the FDA labels say about taking them together
Furosemide and meloxicam
Meloxicam's FDA label of January 29, 2026 names furosemide in its drug interactions section; furosemide's label does not name meloxicam itself but warns about its class (NSAIDs (nonsteroidal anti-inflammatory drugs)). The meloxicam label: “Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. …”
Check it at the source: the furosemide FDA label on DailyMed (effective September 30, 2025, Validus Pharmaceuticals LLC); the meloxicam FDA label on DailyMed (effective January 29, 2026, PD-Rx Pharmaceuticals, Inc.).
What does the furosemide label say about meloxicam?
Furosemide's label does not name meloxicam itself; it warns about its class (NSAIDs (nonsteroidal anti-inflammatory drugs)):
Furosemide label, drug interactionsThere are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs.
Source: FDA drug label (Lasix), Validus Pharmaceuticals LLC, effective September 30, 2025 (SPL set 2c9b4d8f-0770-482d-a9e6-9c616a440b1a), via openFDA; the full label on DailyMed
What does the meloxicam label say about furosemide?
Meloxicam label, drug interactionsIn such high risk patients, monitor for signs of worsening renal function (7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics.
Qamzova label (Nanjing Delova Biotech Co., Ltd., July 16, 2026), drug interactionsDiuretics Clinical Impact: Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis. … Intervention: During concomitant use of QAMZOVA with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions () ].
Source: FDA drug label (Qamzova, NDA217593), Nanjing Delova Biotech Co., Ltd., effective July 16, 2026 (SPL set 385fd779-1be1-49ae-8213-750b96ecc997), via openFDA
Source: FDA drug label (Meloxicam, NDA021530), Emerald Therapeutics, LLC, effective May 29, 2026 (SPL set 55af77dd-2abc-49a6-990c-399d5a5e7a91), via openFDA
Source: FDA drug label (MELOXICAM), PD-Rx Pharmaceuticals, Inc., effective January 29, 2026 (SPL set 19c13159-71f1-2427-e063-6394a90ad44e), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Furosemide | Meloxicam | |
|---|---|---|
| Labeled for | Heart failure, High blood pressure, Edema (fluid retention) | Osteoarthritis, Rheumatoid arthritis, Pain |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.490 per mL 20 mg/2 mL vial | $0.0166 per tablet 7.5 mg tablet |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once